> Details

Finkelmeier, Fabian; Scheiner, Bernhard; Leyh, Catherine; Best, Jan; Fründt, Thorben Wilhelm; Czauderna, Carolin; Beutel, Alica; Bettinger, Dominik; Weiß, Johannes; Meischl, Tobias; Kuetting, Fabian; Waldschmidt, Dirk Thomas; Schultheiß, Michael; Ettrich, Thomas Jens; Weinmann, Arndt; Wege, Henning; Venerito, Marino; Lange, Christian; Pinter, Matthias; Waidmann, Oliver

Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort
  • Contributor: Finkelmeier, Fabian; Scheiner, Bernhard; Leyh, Catherine; Best, Jan; Fründt, Thorben Wilhelm; Czauderna, Carolin; Beutel, Alica; Bettinger, Dominik; Weiß, Johannes; Meischl, Tobias; Kuetting, Fabian; Waldschmidt, Dirk Thomas; Schultheiß, Michael; Ettrich, Thomas Jens; Weinmann, Arndt; Wege, Henning; Venerito, Marino; Lange, Christian; Pinter, Matthias; Waidmann, Oliver
  • Published: American Society of Clinical Oncology (ASCO), 2020
  • Published in: Journal of Clinical Oncology, 38 (2020) 15_suppl, Seite e16668-e16668
  • Language: English
  • DOI: 10.1200/jco.2020.38.15_suppl.e16668
  • ISSN: 0732-183X; 1527-7755
  • Origination:
  • Footnote:
  • Description: e16668 Background: The multikinase inhibitor cabozantinib has been approved by the European Medicines Agency in November 2018 for hepatocellular carcinoma (HCC) prior treated with sorafenib. We report, to our knowledge, for the first time safety and efficacy data of an international, multicenter, real-world cohort of patients with advanced HCC treated with cabozantinib. Methods: Patients with HCC who were treated with cabozantinib were retrospectively identified across 10 centers in Austria and Germany. Patients´ characteristics, side effects, duration of treatment and survival data were analyzed until January 17, 2020. Results: 74 patients were identified of whom 65 patients were male (88%) and 9 were female (12%). The median age at the start of cabozantinib treatment was 66 years. The most common underlying liver diseases included hepatitis C in 15 (20%), hepatitis B in 6 (8%), alcohol in 17 (23%) and NAFLD/NASH in 20 (27%) patients, respectively. 64 patients (86%) had BCLC stage C and 43 patients (58%) were Child Pugh A. Cabozantinib was used as systemic second- and third-line treatment in 37 (50%), and 25 (34%) patients, respectively. In the remaining patients cabozantinib was used in further lines. The median starting dose was 40 mg (20-60 mg). In 26 patients (35%) a dose reduction due to side effects was performed. Following best responses under cabozantinib were documented: partial response in 4 (5%), stable disease in 22 (30%), and progressive disease in 24 (32%) patients, respectively. 24 patients (32%) had not yet been evaluable. The median duration of cabozantinib treatment was 4.4 months. 35 patients (47%) had died at day of data analysis. The median overall survival from start of cabozantinib treatment was 7.7 months. Most common adverse events were fatigue and diarrhea. Conclusions: Cabozantinib treatment was effective, safe and feasible in patients with advanced HCC. Patients in the real life setting had more advanced liver disease – only 58% of patients were Child A. Duration of treatment was similar to the phase 3 trial (CELESTIAL). However, overall survival was shorter, probably due to more advanced liver disease.
  • Access State: Open Access